Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | CPT2 | P23786 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HMGCR | P04035 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BHMT | Q93088 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL433760 | 0.85 | KDM4E (0.54) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL17187568 | 0.83 | KDM4E (0.52) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL1979018 | 0.83 | KDM4E (0.52) | KDM4EFFAR1CPT2TDP1HMGCR | |
| Methane SCHEMBL371521 | 0.83 | KDM4E (0.52) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL16675265 | 0.80 | KDM4E (0.31) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL16305058 | 0.76 | FFAR1 (0.75) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL557257 | 0.75 | KDM4E (0.59) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL30854909 | 0.74 | KDM4E (0.65) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL48109 | 0.74 | KDM4E (0.65) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL16305054 | 0.74 | FFAR1 (0.64) | KDM4EFFAR1CPT2TDP1HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637516-B2 | Betulinic acid proline derivatives as HIV inhibitors | HETERO RESEARCH FOUNDATION (IN) | 2017-05-02 | — | — | US | disclosed |
| US-20150337004-A1 | NOVEL BETULINIC ACID PROLINE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2015-11-26 | — | — | US | disclosed |
| US-20150119373-A1 | NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119373-A1 | NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS | BET1, PGGT1B, RABGGTB | KDM4E 1768/4885FFAR1 3597/4885CPT2 3312/4885 |
| US-20150337004-A1 | NOVEL BETULINIC ACID PROLINE DERIVATIVES AS HIV INHIBITORS | BET1, PRR12, PELP1 | KDM4E 1605/4885FFAR1 4365/4885CPT2 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.